

Resource Summary Report

Generated by [kravitz2](#) on Sep 17, 2026

BD Biosciences: LSR II Flow Cytometer

RRID:SCR_002159

Type: Tool

Proper Citation

BD Biosciences: LSR II Flow Cytometer (RRID:SCR_002159)

Resource Information

URL: <https://www.bd.com/resource.aspx?IDX=17868>

Proper Citation: BD Biosciences: LSR II Flow Cytometer (RRID:SCR_002159)

Description: Benchtop high-performance cell sorter with multiple laser, detector and fluorescence options. Allows detection of 12 parameters (10 color conjugates, forward and sideward scatter).

Abbreviations: LSR II Flow Cytometer

Resource Type: instrument resource

Keywords: flow cytometer, instrument, equipment, hardware

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Specification URL:

<https://drive.google.com/file/d/1iqsXa8XNCYWutCswBRYBWluHGag0IOSx/view?usp=drivesdk>

Resource Name: BD Biosciences: LSR II Flow Cytometer

Resource ID: SCR_002159

Alternate IDs: Model_Number_BD LSR II, SciRes_000152

Alternate URLs: <https://fccf.sitehost.iu.edu/pdf/BDLSRIIUserGuide.pdf>

Old URLs: http://www.rockefeller.edu/fcrc/pdf/BD_LSRII_Brochure_SJ-0142-00.pdf

Record Creation Time: 20220129T080211+0000

Record Last Update: 20260912T195537+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: LSR II Flow Cytometer.

No alerts have been found for BD Biosciences: LSR II Flow Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Hammoudi A, et al. (2026) Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses. *EBioMedicine*, 127, 106269.

Yemelyanenko J, et al. (2026) C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3. *Cancer research*, 86(6), 1372.

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Navarro Negredo P, et al. (2026) Targeting immune cells in the aged brain reveals that engineered cytokine IL-10 enhances neurogenesis and improves cognition. *Immunity*, 59(2), 458.

Nair MS, et al. (2026) Antiviral activity of non-neutralizing antibodies during steady-state HIV-1 infection in humanized mice. *iScience*, 29(7), 116632.

Garg SK, et al. (2026) Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. *Cell reports*, 45(3), 117050.

Zhou L, et al. (2026) p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. *Cancer discovery*, 16(3), 571.

Xue F, et al. (2025) CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. *Cancers*, 17(10).

Jha V, et al. (2025) Substitution of Glutamic Acid at Position 71 of DR β 1*04:01 and Collagen-Specific Tolerance Without Alloreactivity. *Arthritis & rheumatology (Hoboken, N.J.)*, 77(5), 526.

Wang W, et al. (2025) Kindlin-2-Mediated Hematopoiesis Remodeling Regulates Triple-Negative Breast Cancer Immune Evasion. *Molecular cancer research : MCR*, 23(5), 450.

Katkeviciute E, et al. (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. *Cell reports*, 44(3), 115357.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Wischnewski V, et al. (2025) The local microenvironment suppresses the synergy between irradiation and anti-PD1 therapy in breast-to-brain metastasis. *Cell reports*, 44(3), 115427.

Kim AR, et al. (2025) Co-blockade of TGF β and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGF β RI Expression. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3306.

Álvarez-Prado ÁF, et al. (2025) Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. *Cell reports*, 44(9), 116151.

Rodriguez D, et al. (2024) Therapeutic Delivery of Soluble Fractalkine Ameliorates Vascular Dysfunction in the Diabetic Retina. *International journal of molecular sciences*, 25(3).

Füchsl F, et al. (2024) High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. *Nature communications*, 15(1), 10520.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. *Clinical and experimental immunology*.

Rodriguez D, et al. (2024) Fractalkine isoforms differentially regulate microglia-mediated inflammation and enhance visual function in the diabetic retina. *Journal of neuroinflammation*, 21(1), 42.

Nasser AM, et al. (2024) CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(14), 2996.